TAPUR

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

Official title

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Phase

Phase 2

Status

Recruiting

Conditions

Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors

Interventions

Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT); Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT); Olaparib (CLOSED TO ENROLLMENT); Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT); Abemaciclib (CLOSED TO ENROLLMENT); Talazoparib (CLOSED TO ENROLLMENT); Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT); Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT); Futibatinib; Dabrafenib plus Trametinib; Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

Arms

• Group 5 (CSF1R,PDGFR,VEGFR) · Other
• Group 8 (ERBB2) · Other
• Group 9 (BRAF V600E/D/K/R) · Other
• Group 14 (BRCA1/2; ATM) · Other
• Group 16 (MSI-H, high mutational load and others) · Other
• Group 17 (CDKN2A, CDK4, CDK6) · Other
• Group 19 (BRCA1/2, PALB2) · Other
• Group 21 (BRCA1/2, PALB2, ATM, and others) · Other
• Group 24 (ERBB2) · Other
• Group 25 · Other
• Group 26 (BRAF V600 E mutation ) · Other
• Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression) · Other

Enrollment

4,200 (estimated)

Primary outcomes

• Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria

Sponsor

American Society of Clinical Oncology with AstraZeneca, Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Pfizer, Taiho Oncology, Inc., Novartis, Merck Institute for Therapeutic Research, Boehringer Ingelheim, Seattle Genetics (now a wholly owned subsidiary of Pfizer)

Start

Mar 14, 2016

Primary completion

Dec 31, 2027 (estimated)

Results posted

No

Registry record

NCT02693535 · updated Sep 22, 2026

• Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7. PubMed 42842844
• Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15. PubMed 42456088
• Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30. PubMed 42060861
• Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22. PubMed 42018965
• Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15. PubMed 41538762
• Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16. PubMed 41100773
• Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1. PubMed 40610648
• Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16. PubMed 39413339
• Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219. PubMed 39013131
• Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026. PubMed 38865672
• Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15. PubMed 38748939
• Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615. PubMed 38564684
• Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513. PubMed 38354330
• Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385. PubMed 38096472
• Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279. PubMed 38039429
• Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10. PubMed 37561967
• Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25. PubMed 37489819
• Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041. PubMed 37315265
• Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609. PubMed 37027810
• Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505. PubMed 36753688
• Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306. PubMed 36315917
• Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12. PubMed 33844595
• Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7. PubMed 33090333
• Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8. PubMed 33068284